Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
The Omnipod 5 System consists of a tubeless wearable Pod, the Omnipod 5 mobile app, and the Dexcom G6 Continuous Glucose Monitoring System. The Food and Drug Administration (FDA) has cleared the ...
Insulet Corporation’s PODD Omnipod and Omnipod DASH insulin management systems recently received FDA’s approval for their use with Eli Lilly and Company’s LLY Lyumjev (insulin lispro-aabc injection) ...
The Omnipod DASH system consists of a discreet, tubeless, waterproof Pod which is worn on the body, and the Personal Diabetes Manager (PDM), a handheld wireless device used to control the Pod. Insulet ...
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Stock Score Locked: Want to See it? Benzinga Rankings give you vital metrics on any stock – anytime.
The pair of studies evaluating the technology were presented at the American Diabetes Association and simultaneously published in the Journal of Diabetes Science and Technology. The Insulet ...
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today presented ...
Zacks Investment Research on MSN
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
The upcoming report from Insulet (PODD) is expected to reveal quarterly earnings of $1.13 per share, indicating an increase of 25.6% compared to the year-ago period. Analysts forecast revenues of $676 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback